News

21/05/12: Stallergenes remains committed to the recognition of innovative pharmaceutical companies and has joined G5 Health; 2012 – Stallergenes S.A. (Euronext Paris CAC small) today announces...; [more]

04/05/12: Stallergenes announces positive clinical results for its house dust mites immunotherapy tablet; Results of a clinical study (VO67.10) of the house dust mites sublingual...; [more]

STALLERGENES, biopharmaceutical company

Stallergenes is a European biopharmaceutical company specialized in the treatment of severe respiratory allergies with allergen immunotherapy.

Major player in its market, Stallergenes established sublingual immunotherapy and remains the world leader in this area. Since 2003, the company is committed to the Stalair® development program, creating a new therapeutic class that covers 80% of respiratory allergies. These sublingual allergen immunotherapy tablets are registered as product specialties with properties documented in accordance with the Evidence Based Medicine requirements.